<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/29059/kte-x19-phase-1-data-arrived-at-a-cell-dose-improved-safety-profile-achieved-overall-cri-rate-of-84?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

KTE-X19 Phase 1 Data: Arrived At a Cell Dose, Improved Sa...

Name: KTE-X19 Phase 1 Data: Arrived At a Cell Dose, Improved Sa...
Uploaded: 2019-06-02T07:38:51
Duration: 2 min 18 s
Description: Bijal Shah MD Of Moffitt Cancer Center Discusses KTE-X19 Phase 1 Data: Arrived At a Cell Dose, Improved Safety Profile, Achieved Overall CRI Rate Of 84.

00:02:18

Annual Meeting

3 years 115 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/29059/kte-x19-phase-1-data-arrived-at-a-cell-dose-improved-safety-profile-achieved-overall-cri-rate-of-84?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/29059/kte-x19-phase-1-data-arrived-at-a-cell-dose-improved-safety-profile-achieved-overall-cri-rate-of-84?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/29059/kte-x19-phase-1-data-arrived-at-a-cell-dose-improved-safety-profile-achieved-overall-cri-rate-of-84?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/29059?channelName=AnnualCancerMeeting"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190602193851_01b7/video_190602193851_01b7.jpg?cache=15669162971678829655">KTE-X19 Phase 1 Data: Arrived At a Cell Dose, Improved Safety Profile, Achieved Overall CRI Rate Of 84</a>

Link (BBCode):

[url=https://oncologytube.com/v/29059?channelName=AnnualCancerMeeting][img]https://oncologytubecom.cdn.ypt.me/videos/video_190602193851_01b7/video_190602193851_01b7.jpg?cache=15669162971678829655[/img]KTE-X19 Phase 1 Data: Arrived At a Cell Dose, Improved Safety Profile, Achieved Overall CRI Rate Of 84[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Acute Lymphoblastic Leukemia

Description:

Bijal Shah MD Of Moffitt Cancer Center Discusses KTE-X19 Phase 1 Data: Arrived At a Cell Dose, Improved Safety Profile, Achieved Overall CRI Rate Of 84.